The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Pleuropulmonary blastoma: A report on 350 central pathology–confirmed pleuropulmonary blastoma cases by the International Pleuropulmonary Blastoma Registry
Open accessAbstract
BACKGROUND: Pleuropulmonary blastoma (PPB) has 3 subtypes on a tumor progression pathway ranging from type I (cystic) to type II (cystic/solid) and type III (completely solid). A germline mutation in DICER1 is the genetic cause in the majority of PPB cases. METHODS: Patients confirmed to have PPB by central pathology review were included, and their clinical characteristics and outcomes were reported. Germline DICER1 mutations were sought with Sanger sequencing. RESULTS: There were 435 cases, and a central review confirmed 350 cases to be PPB; 85 cases (20%) were another entity. Thirty‐three percent of the 350 PPB cases were type I or type I regressed (type Ir), 35% were type II, and 32% were type III or type II/III. The median ages at diagnosis for type I, type II, and type III patients were 8, 35, and 41 months, respectively. The 5‐year overall survival (OS) rate for type I/Ir patients was 91%; all deaths in this group were due to progression to type II or III. OS was significantly better for type II versus type III (P = .0061); the 5‐year OS rates were 71% and 53%, respectively. Disease‐free survival (DFS) was also significantly better for type II versus type III (P = .0002); the 5‐year DFS rates were 59% and 37%, respectively. The PPB type was the strongest predictor of outcome. Metastatic disease at the diagnosis of types II and III was also an independent unfavorable prognostic factor. Sixty‐six percent of the 97 patients tested had a heterozygous germline DICER1 mutation. In this subset, the DICER1 germline mutation status was not related to the outcome. CONCLUSIONS: Cystic type I/Ir PPB has a better prognosis than type II, and type II has a better outcome than type III. Surveillance of DICER1 carriers may allow the earlier detection of cystic PPB before its progression to type II or III PPB and thereby improve outcomes. Cancer 2015;121:276–85. © 2014 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Individual Comparisons by Ranking Methods
Wilcoxon, F. (1945) · Biometrics Bulletin · doi:10.2307/3001968 · Cited by 15,354
SIFT web server: predicting effects of amino acid substitutions on proteins
Sim, N.-L., Kumar, P., Hu, J., Henikoff, S., Schneider, G., & Ng, P. C. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks539 · Cited by 2,411
DICER1 Mutations in Familial Pleuropulmonary Blastoma
Hill, D. A., Ivanovich, J., Priest, J. R., Gurnett, C. A., Dehner, L. P., Desruisseau, D., Jarzembowski, J. A., Wikenheiser-Brokamp, K. A., Suarez, B. K., Whelan, A. J., et al. (2009) · Science · doi:10.1126/science.1174334 · Cited by 751
Self-citationSlade, I., Bacchelli, C., Davies, H., Murray, A., Abbaszadeh, F., Hanks, S., Barfoot, R., Burke, A., Chisholm, J., Hewitt, M., et al. (2011) · Journal of Medical Genetics · doi:10.1136/jmg.2010.083790 · Cited by 371
Self-citationPleuropulmonary blastoma: A marker for familial disease
Priest, J. R., Watterson, J., Strong, L., Huff, V., Woods, W. G., Byrd, R. L., Friend, S. H., Newsham, I., Amylon, M. D., Pappo, A., et al. (1996) · The Journal of Pediatrics · doi:10.1016/s0022-3476(96)70393-1 · Cited by 229
Self-citationHill, D. A., Jarzembowski, J. A., Priest, J. R., Williams, G., Schoettler, P., & Dehner, L. P. (2008) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181484165 · Cited by 220
Self-citationDICER1 mutations in childhood cystic nephroma and its relationship to DICER1-renal sarcoma
Doros, L. A., Rossi, C. T., Yang, J., Field, A., Williams, G. M., Messinger, Y., Cajaiba, M. M., Perlman, E. J., A Schultz, K., Cathro, H. P., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.242 · Cited by 208
Self-citationAnglesio, M., Wang, Y., Yang, W., Senz, J., Wan, A., Heravi‐Moussavi, A., Salamanca, C., Maines‐Bandiera, S., Huntsman, D., & Morin, G. (2013) · The Journal of Pathology · doi:10.1002/path.4135 · Cited by 178
Pugh, T. J., Yu, W., Yang, J., Field, A. L., Ambrogio, L., Carter, S. L., Cibulskis, K., Giannikopoulos, P., Kiezun, A., Kim, J., et al. (2014) · Oncogene · doi:10.1038/onc.2014.150 · Cited by 175
Self-citation
Cited by
Schultz, K. A. P., Williams, G. M., Kamihara, J., Stewart, D. R., Harris, A. K., Bauer, A. J., Turner, J., Shah, R., Schneider, K., Schneider, K. W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3089 · Cited by 378
Self-citationPredisposition to cancer in children and adolescents
Kratz, C. P., Jongmans, M. C., Cavé, H., Wimmer, K., Behjati, S., Guerrini-Rousseau, L., Milde, T., Pajtler, K. W., Golmard, L., Gauthier-Villars, M., et al. (2021) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(20)30275-3 · Cited by 129
Metadata
- Authors
- Messinger, Y. H., Stewart, D. R., Priest, J. R., Williams, G. M., Harris, A. K., Schultz, K. A. P., Yang, J., Doros, L., Rosenberg, P. S., Hill, D. A., & Dehner, L. P.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2014-09-10
- Volume
- 121
- Issue
- 2
- Pages
- 276-285
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1487815750
- Cited by
- 341
- References
- 19
- FWCI
- 17.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pleuropulmonary blastoma: A report on 350 central pathology–confirmed pleuropulmonary blastoma cases by the International Pleuropulmonary Blastoma Registry. https://app.cochat.ai/papers/10.1002/cncr.29032
- The paper
- Messinger, Y. H., Stewart, D. R., Priest, J. R., Williams, G. M., Harris, A. K., Schultz, K. A. P., Yang, J., Doros, L., Rosenberg, P. S., Hill, D. A., & Dehner, L. P. (2015). Pleuropulmonary blastoma: A report on 350 central pathology–confirmed pleuropulmonary blastoma cases by the International Pleuropulmonary Blastoma Registry. Cancer. https://doi.org/10.1002/cncr.29032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.